<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212795</url>
  </required_header>
  <id_info>
    <org_study_id>DW224-I-7</org_study_id>
    <nct_id>NCT02212795</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin</brief_title>
  <acronym>Bacteriocide</acronym>
  <official_title>Phase I Study of Pharmacokinetics and Bacteriocidal Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of
      Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy
      volunteer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, open label, single dose, crossover phase I clinical study to compare the
      pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and
      Levofloxacin 250mg after oral administration in healthy volunteer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUC</measure>
    <time_frame>Predose(0), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours</time_frame>
    <description>Maximum of Concentration(Cmax) Area Under Plasma Concentration-Time Curve(AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Plasma</measure>
    <time_frame>Predose(0), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours</time_frame>
    <description>Maximum drug concentration time(Tmax) Half-time(t1/2) Apparent renal clearance(CL/F) Apparent volume of distribution(Vz/F) Mean of Retention Time(MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of Urine</measure>
    <time_frame>Predose(-12-0), 0-6, 6-12, 12-24, 24-36, 48-72, 72-96, 96-120 hours</time_frame>
    <description>Umax, Cumulative Amount Excreted(Ae), Fraction of the dose excreted unchanged(fe), Renal Clearance(CLr), Urinary Hydrogen exponent(Urinary pH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bactericidal Activity Profile of Urine</measure>
    <time_frame>Predose(-12-0), 0-6, 6-12, 12-24, 24-36, 48-72, 72-96, 96-120 hours</time_frame>
    <description>Urinary Bactericidal Titers(UBT) Area under the UBT-versus-time curve(AUBT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin 183mg</intervention_name>
    <description>Zabofloxacin 183mg single dose</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_label>C Group</arm_group_label>
    <other_name>Zabolante 183mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 250mg</intervention_name>
    <description>Levofloxacin 250mg single dose</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_label>C Group</arm_group_label>
    <other_name>Cravit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin 367mg</intervention_name>
    <description>Zabofloxacin 367mg single dose</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_label>C Group</arm_group_label>
    <other_name>Zabolante 367mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy adult within the range of 19 to 65 years old at the time of screening

          -  Body Mass Index(BMI)=17.5~30.5kg/m2, one with weight of more than 55kg (BMI= kg/(m)2)

          -  Congenital or chronic diseases within the last three years, there is no medical
             examination results of popular characters with no psychotic symptoms or findings

          -  Doctor checks conducted hematology, blood chemistry, urinalysis and laboratory tests,
             including an electrocardiogram(EKG) performed during screening tests such as a
             suitable test subjects who judged

          -  The purpose of the test participants prior to testing, information, and to hear about
             the free will fully explain to participate in this study, according to the
             Institutional Review Board(IRB)-approved consent form signed by the parties in writing

        Exclusion Criteria:

          -  One with clinically significant blood, kidneys, endocrine, respiratory,
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or
             allergic disease (but ,except for untreated seasonal allergies of asymptomatic at the
             time of administration) with medical history or evidence

          -  One with gastrointestinal disease(Such as esophageal stricture or achalasia of the
             esophagus disease, Crohn disease) to affect drug absorption or surgery(but, excluding
             simple appendectomy or hernia surgery) with medical history

          -  Alanine Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 times the upper
             limit of the normal range

          -  Within 6 months, 210 g / week of alcohol in excess of a history of regular characters
             (beer (5%) 1 cup (250 mL) = 10 g, soju(20%) 1 cup (50 mL) = 8 g, Wine (12%) 1 cup (125
             mL) = 12 g)

          -  Take part in other clinical trials within two months

          -  Systolic Blood Pressure(SBP) ≥ 140 mmHg or Diastolic Blood Pressure (DBP) ≥ 90 mmHg

          -  The great history of alcohol or drug abuse within 1 year

          -  Taking medication of drug-metabolizing enzymes that are known to significantly induce
             or inhibit within 30 days

          -  More than 20 cigarettes a day smoker

          -  Taking medication of a prescription drug or nonprescription within 10 days,

          -  Within two months the whole blood donation have, within one month of the apheresis
             donation have

          -  Participate in clinical trials to test drug administration and may be at increased
             risk due to interpretation of test results, or may interfere with severe supply /
             chronic medical or mental condition or abnormal laboratory test values in character

          -  Pregnant women and lactating mothers

          -  Described lifestyle in this protocol can comply with or can not

          -  One with other investigator judge to unsuitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MinGul Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

